Sanofi India Limited (SANOFI.NS)
INR 6082.6
(-0.65%)
INR 6082.6
(-0.65%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 28.51 Billion INR | 2.92% |
| 2022 | 27.7 Billion INR | -5.28% |
| 2021 | 29.24 Billion INR | 1.95% |
| 2020 | 28.68 Billion INR | -4.81% |
| 2019 | 30.13 Billion INR | 9.9% |
| 2018 | 27.42 Billion INR | 11.02% |
| 2017 | 24.7 Billion INR | 5.47% |
| 2016 | 23.42 Billion INR | 7.63% |
| 2015 | 21.75 Billion INR | 10.77% |
| 2014 | 19.64 Billion INR | 9.07% |
| 2013 | 18.01 Billion INR | 14.79% |
| 2012 | 15.69 Billion INR | 27.59% |
| 2011 | 12.29 Billion INR | 13.35% |
| 2010 | 10.84 Billion INR | 11.35% |
| 2009 | 9.74 Billion INR | -0.9% |
| 2008 | 9.83 Billion INR | 12.56% |
| 2007 | 8.73 Billion INR | -1.18% |
| 2006 | 8.83 Billion INR | 9.42% |
| 2005 | 8.07 Billion INR | 9.91% |
| 2004 | 7.34 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 7.32 Billion INR | 5.55% |
| 2024 Q2 | 4.63 Billion INR | -36.71% |
| 2023 Q1 | 7.36 Billion INR | 9.61% |
| 2023 FY | 28.51 Billion INR | 2.92% |
| 2023 Q2 | 7.06 Billion INR | -4.13% |
| 2023 Q4 | 6.93 Billion INR | -2.9% |
| 2023 Q3 | 7.14 Billion INR | 1.2% |
| 2022 FY | 27.7 Billion INR | -5.28% |
| 2022 Q2 | 6.99 Billion INR | -1.09% |
| 2022 Q3 | 6.91 Billion INR | -1.06% |
| 2022 Q4 | 6.71 Billion INR | -2.89% |
| 2022 Q1 | 7.07 Billion INR | 7.79% |
| 2021 Q1 | 7.25 Billion INR | 5.52% |
| 2021 Q3 | 7.54 Billion INR | -4.38% |
| 2021 Q4 | 6.55 Billion INR | -13.07% |
| 2021 Q2 | 7.89 Billion INR | 8.83% |
| 2021 FY | 29.24 Billion INR | 1.95% |
| 2020 FY | 28.68 Billion INR | -4.81% |
| 2020 Q4 | 6.87 Billion INR | 0.09% |
| 2020 Q3 | 6.86 Billion INR | -3.36% |
| 2020 Q2 | 7.1 Billion INR | -9.43% |
| 2020 Q1 | 7.84 Billion INR | 1.95% |
| 2019 Q4 | 7.69 Billion INR | -1.23% |
| 2019 Q1 | 7.17 Billion INR | 6.0% |
| 2019 Q2 | 7.47 Billion INR | 4.27% |
| 2019 Q3 | 7.79 Billion INR | 4.17% |
| 2019 FY | 30.13 Billion INR | 9.9% |
| 2018 Q2 | 6.83 Billion INR | 10.67% |
| 2018 Q4 | 6.76 Billion INR | -9.02% |
| 2018 FY | 27.42 Billion INR | 11.02% |
| 2018 Q1 | 6.17 Billion INR | -7.86% |
| 2018 Q3 | 7.43 Billion INR | 8.81% |
| 2017 Q3 | 6.67 Billion INR | 11.14% |
| 2017 Q2 | 6 Billion INR | 8.63% |
| 2017 Q1 | 5.52 Billion INR | 0.2% |
| 2017 FY | 24.7 Billion INR | 5.47% |
| 2017 Q4 | 6.7 Billion INR | 0.43% |
| 2016 Q4 | 5.51 Billion INR | -11.6% |
| 2016 FY | 23.42 Billion INR | 7.63% |
| 2016 Q3 | 6.24 Billion INR | 2.66% |
| 2016 Q2 | 6.08 Billion INR | 11.68% |
| 2016 Q1 | 5.44 Billion INR | 4.21% |
| 2015 Q3 | 5.85 Billion INR | 6.57% |
| 2015 FY | 21.75 Billion INR | 10.77% |
| 2015 Q4 | 5.22 Billion INR | -10.82% |
| 2015 Q1 | 4.88 Billion INR | -2.0% |
| 2015 Q2 | 5.49 Billion INR | 12.44% |
| 2014 Q2 | 5.05 Billion INR | 13.69% |
| 2014 Q3 | 5.14 Billion INR | 1.8% |
| 2014 FY | 19.64 Billion INR | 9.07% |
| 2014 Q4 | 4.98 Billion INR | -3.12% |
| 2014 Q1 | 4.44 Billion INR | -7.4% |
| 2013 Q4 | 4.8 Billion INR | -3.41% |
| 2013 Q2 | 4.35 Billion INR | 12.11% |
| 2013 Q1 | 3.88 Billion INR | -18.43% |
| 2013 FY | 18.01 Billion INR | 14.79% |
| 2013 Q3 | 4.97 Billion INR | 14.32% |
| 2012 Q3 | 3.96 Billion INR | 6.01% |
| 2012 Q4 | 4.75 Billion INR | 19.97% |
| 2012 Q2 | 3.74 Billion INR | 9.26% |
| 2012 Q1 | 3.42 Billion INR | 1.32% |
| 2012 FY | 15.69 Billion INR | 27.59% |
| 2011 Q2 | 3.02 Billion INR | 0.0% |
| 2011 Q4 | 3.37 Billion INR | 8.07% |
| 2011 Q3 | 3.12 Billion INR | 3.27% |
| 2011 FY | 12.29 Billion INR | 13.35% |
| 2010 FY | 10.84 Billion INR | 11.35% |
| 2009 FY | 9.74 Billion INR | -0.9% |
| 2008 FY | 9.83 Billion INR | 12.56% |
| 2007 FY | 8.73 Billion INR | -1.18% |
| 2006 FY | 8.83 Billion INR | 9.42% |
| 2005 FY | 8.07 Billion INR | 9.91% |
| 2004 FY | 7.34 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Abbott India Limited | 58.48 Billion INR | 51.254% |
| Cipla Limited | 257.74 Billion INR | 88.938% |
| Gland Pharma Limited | 56.64 Billion INR | 49.669% |
| GlaxoSmithKline Pharmaceuticals Limited | 34.53 Billion INR | 17.448% |
| Kopran Limited | 6.14 Billion INR | -363.901% |
| Marksans Pharma Limited | 21.77 Billion INR | -30.94% |
| NGL Fine-Chem Limited | 3.38 Billion INR | -741.806% |
| Pfizer Limited | 21.93 Billion INR | -29.999% |
| SMS Pharmaceuticals Limited | 7.09 Billion INR | -301.98% |
| TTK Healthcare Limited | 7.52 Billion INR | -278.736% |